Amgen Demands Injunction In Biosimilar Suit

Law360, New York (February 6, 2015, 2:54 PM ET) -- Amgen Inc. asked a California federal judge on Friday to grant it a preliminary injunction in its fight with Sandoz Inc. over a biosimilar version of Neupogen, arguing that Sandozâ€™s market entry will be illegal and will irreparably harm Amgen and that an injunction is in the public interest.



The biopharmaceutical company said in its motion that Sandoz can begin marketing its product as soon as March 8, but that the hearing on cross-motions for judgment is only set for March 2. Amgen contends that Sandoz...

To view the full article, register now.